BCR and posterior cortical atrophy: While these developments are helpful, level-one evidence to guide clinicians prescribing treatment for BCR is lacking; thus clinical factors, such as PSADT, GS, and genomic testing can be applied to estimate the risk for PCa progression [73, 89].